Could tiny cell particles unlock secrets of gaucher disease?
NCT ID NCT05843552
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study looks at tiny particles called extracellular vesicles in people with Gaucher disease, carriers, and healthy volunteers. Researchers want to see if these particles differ between groups and if they can help explain brain inflammation linked to the disease. The study involves 30 participants and does not test any treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could point toward new biomarkers for Gaucher disease and related neurological conditions.
- What could go wrong
- This is a small, early observational study with only 30 participants. It is not testing a treatment, so it may not lead directly to any new therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GAUCHER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55414, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we outsmart Gaucher's hidden toll on lungs, bones, and brain?
- Cough medicine repurposed: ambroxol registry launches for rare brain diseases
- Do patients understand their home infusion guides? new survey aims to find out
- Home infusions may help patients stick to treatment
- Japanese study checks safety of gaucher drug VPRIV in Real-World use
- Blood test uncovers rare diseases in patients with mysterious enlarged spleen